Abstract
Triple combination therapy with hydroxychloroquine, sulfasalazine, and methotrexate (MTX) has been shown in double-blind, placebo-controlled studies to be significantly superior to MTX alone (Paulus 50% responses of 77% versus 33%). In long-term follow-up studies, this therapy has now been shown to be well-tolerated with continued efficacy in the majority of patients.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Antirheumatic Agents / adverse effects
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Rheumatoid / drug therapy*
-
Drug Therapy, Combination
-
Female
-
Humans
-
Hydroxychloroquine / adverse effects
-
Hydroxychloroquine / therapeutic use*
-
Male
-
Methotrexate / adverse effects
-
Methotrexate / therapeutic use*
-
Middle Aged
-
Sulfasalazine / adverse effects
-
Sulfasalazine / therapeutic use*
-
Time Factors
-
Treatment Outcome
Substances
-
Antirheumatic Agents
-
Sulfasalazine
-
Hydroxychloroquine
-
Methotrexate